# Medico-economic Impact of Screening Atopobium Vaginae and Gardnerella Vaginalis in Molecular Biology by "Point-of-care" During Pregnancy

> **NCT02288832** · PHASE2,PHASE3 · COMPLETED · sponsor: **Assistance Publique Hopitaux De Marseille** · enrollment: 6800 (actual)

## Conditions studied

- Low Risk of Preterm Delivery

## Interventions

- **OTHER:** -self-collected vaginal samples
- **DRUG:** zithromax
- **OTHER:** usual practices

## Key facts

- **NCT ID:** NCT02288832
- **Lead sponsor:** Assistance Publique Hopitaux De Marseille
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-06
- **Primary completion:** 2018-07-01
- **Final completion:** 2022-10-21
- **Target enrollment:** 6800 (ACTUAL)
- **Last updated:** 2023-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02288832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02288832, "Medico-economic Impact of Screening Atopobium Vaginae and Gardnerella Vaginalis in Molecular Biology by "Point-of-care" During Pregnancy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02288832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*